More than 2 years since the original trial data for lecanemab in Alzheimer's disease was published,1 and over 1·5 years since approval by the US Food and Drug Administration, brain volume data have ...

Alterations in the growth rates of insects due to drug exposure could introduce bias in post-mortem interval (PMI) estimations if the influence of drugs is overlooked. Incorrect PMI estimations might, ...